deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 3-arm NCT01308294

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321)

Vaccination of Melanoma Patients (Stage II-IV) With ImmuFact IMP321, Tumor Antigenic Peptides and Montanide

Sponsor: Centre Hospitalier Universitaire Vaudois

Conditions Melanoma
Interventions 2 vaccine injections in 1 limb 2 vaccine injections in distinct limbs
Updated 11 times since 2017 Last updated: May 26, 2020 Started: Jun 30, 2010 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low enrollment rate

Other terminated trials from Centre Hospitalier Universitaire Vaudois

See all terminations from Centre Hospitalier Universitaire Vaudois

Other Melanoma trials with similar outcome

Browse all Melanoma trials

This PHASE1/PHASE2 trial investigates Melanoma and is currently terminated or withdrawn. Centre Hospitalier Universitaire Vaudois leads this study, which shows 11 recorded versions since 2010 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~Apr 2020 · 22 months · monthly snapshotTerminated~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshotTerminated~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshotTerminated~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshotTerminated~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshotTerminated~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE1_PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 6 earlier versions

  1. Oct 2021 — Dec 2021 [monthly]

    Terminated PHASE1_PHASE2

  2. Jan 2021 — Oct 2021 [monthly]

    Terminated PHASE1_PHASE2

  3. Jul 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

  4. Apr 2020 — Jul 2020 [monthly]

    Terminated PHASE1_PHASE2

  5. Jun 2018 — Apr 2020 [monthly]

    Terminated PHASE1_PHASE2

  6. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE1_PHASE2

    First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Centre Hospitalier Universitaire Vaudois
  • Immutep S.A.S.
Data source: Centre Hospitalier Universitaire Vaudois

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations